@article{ATM19463,
author = {Yuki Kataoka and Katsuya Hirano},
title = {Which criteria should we use to evaluate the efficacy of immunecheckpoint inhibitors?},
journal = {Annals of Translational Medicine},
volume = {6},
number = {11},
year = {2018},
keywords = {},
abstract = {Immune-checkpoint inhibitors (ICI) have innovated the treatment of many different types of advanced cancer. Two important distinctions between ICI and other modalities are durable response (DR) and pseudoprogression (1,2).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/19463}
}